ReviewCurrent topics in medicinal chemistry2016
Biomarkers in the Management of Difficult Asthma.
Review in Current topics in medicinal chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 53 citations in OpenAlex.
- Trial
- Clinical phenotyping of asthma patients with elevated sputum eosinophils and low blood eosinophils: a post-hoc analysis of the multicentre ATLANTIS cohort.EBioMedicine · 2026Article
- A Multilevel Redox-Based Prognostic Model for Asthma Severity: From Genotype to Serum Biomarkers.Biomedicines · 2026Review
- Metabolomics in Animal Models of Bronchial Asthma and Its Translational Importance for Clinics.International journal of molecular sciences · 2023Review
- Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab.Paediatric drugs · 2023Review
- Phenotype overlap in the natural history of asthma.European respiratory review : an official journal of the European Respiratory Society · 2023Review
- T2-Low Asthma: A Discussed but Still Orphan Disease.Biomedicines · 2023Review
- Severe Asthmatic Responses: The Impact of TSLP.International journal of molecular sciences · 2023Review
- How does cigarette smoking affect airway remodeling in asthmatics?Tobacco induced diseases · 2023Review
- Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µLThe European respiratory journal · 2022Article
- Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation.The European respiratory journal · 2022Article
- Identification of Key Signaling Pathways and Genes in Eosinophilic Asthma and Neutrophilic Asthma by Weighted Gene Co-Expression Network Analysis.Frontiers in molecular biosciences · 2022Article
- Which Therapy for Non-Type(T)2/T2-Low Asthma.Journal of personalized medicine · 2021Review
- Metabolomics, Microbiota, and In Vivo and In Vitro Biomarkers in Type 2 Severe Asthma: A Perspective Review.Metabolites · 2021Review
- An update on the diagnostic biomarkers for asthma.Journal of family medicine and primary care · 2021Review
- Latest Progresses in Allergic Diseases Biomarkers: Asthma and Atopic Dermatitis.Frontiers in pharmacology · 2021Review
- Targeting NLRP3 Inflammasome Activation in Severe Asthma.Journal of clinical medicine · 2019Review
- Paucigranulocytic asthma: Uncoupling of airway obstruction from inflammation.The Journal of allergy and clinical immunology · 2019Review
- Asthma and Corticosteroid Responses in Childhood and Adult Asthma.Clinics in chest medicine · 2019Review
- Features of Oxidative and Nitrosative Metabolism in Lung Diseases.Oxidative medicine and cellular longevity · 2019Review
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Difficult asthma is a heterogeneous disease of the airways including various types of bronchial inflammation and various degrees of airway remodeling. Therapeutic response of severe asthmatics can be predicted by the use of biomarkers of Type2-high or Type2-low inflammation. Based on sputum cell analysis, four inflammatory phenotypes have been described. As induced sputum is timeconsuming and expensive technique, surrogate biomarkers are useful in clinical practice. Eosinophilic phenotype is likely to reflect ongoing adaptive immunity in response to allergen. Several biomarkers of eosinophilic asthma are easily available in clinical practice (blood eosinophils, serum IgE, exhaled nitric oxyde, serum periostin). Neutrophilic asthma is thought to reflect innate immune system activation in response to pollutants or infectious agents while paucigranulocytic asthma is thought to be not inflammatory and characterized by smooth muscle dysfunction. We currently lack of user-friendly biomarkers of neutrophilic asthma and airway remodeling. In this review, we summarize the biomarkers available for the management of difficult asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.